BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28275479)

  • 1. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis.
    Li D; Zhu X; Wang H; Qiu M; Li N
    J Thorac Dis; 2017 Feb; 9(2):310-317. PubMed ID: 28275479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis.
    Li S; Zhu R; Li D; Li N; Zhu X
    J Thorac Dis; 2018 Jun; 10(6):3701-3713. PubMed ID: 30069368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
    Gray PJ; Mak RH; Yeap BY; Cryer SK; Pinnell NE; Christianson LW; Sher DJ; Arvold ND; Baldini EH; Chen AB; Kozono DE; Swanson SJ; Jackman DM; Alexander BM
    Lung Cancer; 2014 Aug; 85(2):239-44. PubMed ID: 24974152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.
    Petrelli F; Ghidini A; Cabiddu M; Tomasello G; De Stefani A; Bruschieri L; Vitali E; Ghilardi M; Borgonovo K; Barni S; Trevisan F
    Lung Cancer; 2018 Dec; 126():194-200. PubMed ID: 30527187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Spaggiari L; Bertolaccini L; Facciolo F; Gallina FT; Rea F; Schiavon M; Margaritora S; Congedo MT; Lucchi M; Ceccarelli I; Alloisio M; Bottoni E; Negri G; Carretta A; Cardillo G; Ricciardi S; Ruffini E; Costardi L; Muriana G; Viggiano D; Rusca M; Ventura L; Marulli G; De Palma A; Rosso L; Mendogni P; Crisci R; De Vico A; Maniscalco P; Tamburini N; Puma F; Ceccarelli S; Voltolini L; Bongiolatti S; Morelli A; Londero F
    Lung Cancer; 2021 Apr; 154():29-35. PubMed ID: 33610120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
    Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
    Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
    Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution.
    Yegya-Raman N; Aisner J; Kim S; Sayan M; Li D; Langenfeld J; Patel M; Malhotra J; Jabbour SK
    Adv Radiat Oncol; 2019; 4(3):541-550. PubMed ID: 31360811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer.
    Jones GD; Lengel HB; Hsu M; Tan KS; Caso R; Ghanie A; Connolly JG; Bains MS; Rusch VW; Huang J; Park BJ; Gomez DR; Jones DR; Rocco G
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
    Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB
    Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang C; Ma N; Zhang Q; Zheng K; Sun C; Tang X; Li X; Zhao J
    J Thorac Dis; 2021 Oct; 13(10):5899-5910. PubMed ID: 34795938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J
    Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Brachytherapy with Iodine-125 Seeds and Systemic Chemotherapy versus Systemic Chemotherapy Alone for Synchronous Extracranial Oligometastatic Non-Small Cell Lung Cancer.
    Li H; Duan Z; Zhao C; Fang W; Jia Y; Li X; Kong F; Zhao L
    Cancer Manag Res; 2020; 12():8209-8220. PubMed ID: 32982417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy.
    Bai H; Xu J; Yang H; Jin B; Lou Y; Wu D; Han B
    Onco Targets Ther; 2016; 9():4207-13. PubMed ID: 27471395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.